Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial.

Hirooka, Yoshiki; Kawashima, Hiroki; Ohno, Eizaburo; Ishikawa, Takuya; Kamigaki, Takashi; Goto, Shigenori; Takahara, Masashi; Goto, Hidemi

Hirooka, Yoshiki; Kawashima, Hiroki; Ohno, Eizaburo; Ishikawa, Takuya; Kamigaki, Takashi; Goto, Shigenori; Takahara, Masashi; Goto, Hidemi.

Afiliación

Hirooka Y; Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan.
Kawashima H; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ohno E; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ishikawa T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kamigaki T; Seta Clinic, Tokyo, Japan.
Goto S; Department of Next Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Takahara M; Seta Clinic, Tokyo, Japan.
Goto H; Medinet Medical Institute, MEDINET Co. Ltd., Yokohama, Japan.

Oncotarget ; 9(2): 2838-2847, 2018 Jan 05.

Article en En | MEDLINE | ID: mdl-29416816